Moir R D, Martins R N, Bush A I, Small D H, Milward E A, Rumble B A, Multhaup G, Beyreuther K, Masters C L
Department of Pathology, University of Melbourne, Parkville, Australia.
J Neurochem. 1992 Oct;59(4):1490-8. doi: 10.1111/j.1471-4159.1992.tb08465.x.
The major component of the amyloid deposition that characterizes Alzheimer's disease is the 4-kDa beta A4 protein, which is derived from a much larger amyloid protein precursor (APP). A procedure for the complete purification of APP from human brain is described. The same amino terminal sequence of APP was found in two patients with Alzheimer's disease and one control subject. Two major forms of APP were identified in human brain with apparent molecular masses of 100-110 kDa and 120-130 kDa. Soluble and membrane fractions of brain contained nearly equal amounts of APP in both humans and rats. Immunoprecipitation with carboxyl terminus-directed antibodies indicates that the soluble forms of APP are truncated. Carboxyl terminus truncation of membrane-associated forms of human brain APP was also found to occur during postmortem autolysis. The availability of purified human brain APP will facilitate the investigation of its normal function and the events that lead to its abnormal cleavage in patients with Alzheimer's disease.
构成阿尔茨海默病特征性淀粉样沉积的主要成分是4 kDa的β淀粉样蛋白A4,它源自一种大得多的淀粉样蛋白前体(APP)。本文描述了一种从人脑中完全纯化APP的方法。在两名阿尔茨海默病患者和一名对照受试者中发现了相同的APP氨基末端序列。在人脑中鉴定出两种主要形式的APP,其表观分子量分别为100 - 110 kDa和120 - 130 kDa。在人和大鼠的脑中,APP在可溶性组分和膜组分中的含量几乎相等。用羧基末端定向抗体进行免疫沉淀表明,APP的可溶性形式是截短的。还发现人脑APP的膜相关形式在死后自溶过程中会发生羧基末端截短。纯化的人脑APP的可得性将有助于研究其正常功能以及导致阿尔茨海默病患者中其异常切割的事件。